29198-41-2

Usage

Uses

Used in Pharmaceutical Industry:
1,3-Benzothiazol-2-ylmethylamine hydrochloride serves as a crucial building block in the synthesis of various pharmaceuticals. Its unique structure contributes to the development of new drugs, enhancing the therapeutic potential of medicinal compounds.
Used in Pesticide Production:
In the agrochemical sector, 1,3-Benzothiazol-2-ylmethylamine hydrochloride acts as a key intermediate in the production of pesticides. Its incorporation aids in the creation of effective pest control agents, thereby supporting agricultural productivity and crop protection.
Used in Chemical Research:
1,3-Benzothiazol-2-ylmethylamine hydrochloride is utilized as a reagent in chemical research. It facilitates various experimental procedures and reactions, contributing to the advancement of scientific knowledge and the discovery of new chemical entities.
Used in Dye and Pigment Manufacturing:
1,3-Benzothiazol-2-ylmethylamine hydrochloride also finds application as an intermediate in the production of dyes and pigments. Its role in this industry is vital for creating a diverse palette of colors used in various manufacturing processes, from textiles to plastics.
Safety and Handling:
Given its chemical nature, 1,3-Benzothiazol-2-ylmethylamine hydrochloride should be handled and stored according to standard laboratory safety practices to ensure the well-being of individuals and the integrity of experiments.

InChI:InChI=1/C8H8N2S.ClH/c9-5-8-10-6-3-1-2-4-7(6)11-8;/h1-4H,5,9H2;1H

Upstream product

• 623-33-6 glycine ethyl ester hydrochloride 
• 137-07-5 2-amino-benzenethiol 

Downstream Products

• 1203603-89-7 N-(1,3-benzothiazol-2-ylmethyl)-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazin-3-amine 
• 1203603-90-0 N-(1,3-Benzothiazol-2-ylmethyl)-5-[2-chloro-5-(trifluoromethyl)phenyl]-1,2,4-triazin-3-amine 

Relevant academic research and scientific papers

Catalytic Staudinger Reduction at Room Temperature

We report an efficient catalytic Staudinger reduction at room temperature that enables the preparation of a structurally diverse set of amines from azides in excellent yields. The reaction is based on the use of catalytic amounts of triphenylphosphine as a phosphine source and diphenyldisiloxane as a reducing agent. Our catalytic Staudinger reduction exhibits a high chemoselectivity, as exemplified by reduction of azides over other common functionalities, including nitriles, alkenes, alkynes, esters, and ketones.

New bifunctional metalloproteinase inhibitors: An integrated approach towards biological improvements and cancer therapy

The key role of some matrix metalloproteinases (MMPs) on several pathological processes, including carcinogenesis and tumor growth, makes the development of MMP inhibitors (MMPIs) an attractive approach for cancer therapy. We present herein an integrated approach for the development of a new series of inhibitors of MMP2 and MMP14, two enzymes over-expressed by human ovarian cancer. As a first step, a new series of single model compounds bearing different zinc-binding groups (ZBGs), such as carboxylic, hydroxamic acid, hydrazide and sulfonylhydrazide groups, were studied and revealed reasonably good capacity for the Zn(II) chelation in solution and for the MMP inhibition. Aimed at further reinforcing the biological activity of these MMPIs as anti-cancer agents, a selection of those models was extra-functionalized with benzothiazole (BTA), a group with recognized antitumor activity. Analysis of the results obtained for these bifunctional compounds, in particular the inhibitory activity against MMP2 and MMP14 as well as the anti-proliferative activity on the A2780 ovarian cancer cell line, allowed to understand the activity dependence on the type of ZBG, as well as the relevance of the BTA moiety. Overall, the evidenced BTA-associated activity improvements on enzyme inhibition and cell antiproliferactivity, combined with the hydrolytic stability revealed by the hydrazide group, suggest that these new bifunctional BTA-hydrazide derivatives should be taken in consideration for the development of new generations of MMPIs with anti-cancer activity.